ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly unrecognized stock-based compensation cost ($M) ($M)
Form 10-K Stock-Based Compensation Note
Latest, FY2025
554
Period ended Dec 31, 2025
Change on a year earlier
+14.2%
485 in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized stock-based compensation cost ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 554 | +14.2% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 485 | +76.2% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 275 | +24.2% | Form 10-K (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 222 | +37.3% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 161 | -9.9% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 179 | +32.8% | Form 10-K (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 135 | +20.2% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 112 | -5.7% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 119 | – | Form 10-K (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Unrecognized stock-based compensation cost ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rsu_unrecognized_cost
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.